In our population-based study, there was no OS difference in patients with stage IV NSCLC and PD-L1 TPS ≥ 50% who were treated with first-line pembrolizumab and dosed at Q3W or Q6W intervals. Here, CD274 is linked to non-small cell lung carcinoma.